Bookmark
Forward
QuickView for Trabectedin (compound)
PubChem
| Name: | trabectedin |
|---|---|
| PubChem Compound ID: | 10485278 |
| Molecular formula: | C39H43N3O11S |
| Molecular weight: | 761.838 g/mol |
DrugBank
Identification
| Name: | trabectedin |
|---|---|
| Name (isomeric): | DB05109 |
| Drug Type: | small molecule |
| Synonyms: |
Ecteinascidin 743; Ecteinascidin; ET743; ET-743; NSC 684766
|
| Brand: | Yondelis |
| Category: | Antineoplastic Agents, Alkylating |
| CAS number: | 114899-77-3 |
Pharmacology
| Indication: | Indicated for treatment of advanced soft tissue sarcoma in patients refractory to or unsuitable to receive anthracycline or ifosfamide chemotherapy in Europe, Russia and South Korea. Approved for orphan drug status by the U.S. FDA for treatment of soft tissue sarcomas and ovarian cancer. Investigated for use/treatment in cancer/tumors (unspecified), gastric cancer, ovarian cancer, pediatric indications, sarcoma, and solid tumors. |
|---|---|
| Pharmacology: | Two of the rings in the drug's structure allows it to covalently bind to the minor groove of DNA. The third ring protrudes from the DNA which lets it interact with nearby nuclear proteins. This has the additive effect of blocking cell division at the G2 phase. |
| Mechanism of Action: |
Trabectedin interacts with the minor groove of DNA and alkylates guanine at the N2 position, which bends towards the major groove. In this manner, it is thought that the drug affects various transcription factors involved in cell proliferation, particularly via the transcription-coupled nucleotide excision repair system. Trabectedin blocks the cell...
show more » |
| Absorption: | Administered intravenously. |
| Protein binding: | 94 to 98% |
| Half Life: | 33-50 hours |
Targets
Enzymes
